BrightSpring Health Services delivered another emphatic beat-and-raise in the third quarter. Adjusted EPS of $0.54 topped the $0.45 consensus by 20.0% and grew 80.0% year over year. Revenue of $4.213 billion beat expectations by 9.2% and rose 26.4%, an acceleration from roughly 23% growth in the second quarter. Management raised full-year guidance for the fourth consecutive time, lifting revenue to $15.9-$16.125 billion from $15.1-$15.425 billion and Adjusted EBITDA to $850-$860 million from $820-$845 million. The central tension is that the fundamentals keep improving while the stock has gone the other way. Shares fell 13.3% from the open after the July report, and investor enthusiasm cooled meaningfully heading into this print.

The quality of the quarter holds up on most measures, though the composition deserves scrutiny. GAAP diluted EPS from continuing operations rose to $0.46 from $0.17, so the improvement is not merely an adjustment story. Adjusted EBITDA climbed 42% to $228 million. Operating cash flow nearly doubled to $204 million, and leverage fell to 1.79x from 2.15x in June and 2.99x at year-end.

Underneath, however, Pharmacy Solutions growth came almost entirely from price and mix rather than volume:

• Prescriptions dispensed rose just 2%.
• Revenue per script jumped 24%.
• Gross profit per script rose 27%.

Management attributes those per-script gains to a richer specialty mix, particularly branded limited-distribution drugs (LDDs). The guidance raise also shows how margin-thin the incremental revenue is. The revenue midpoint rose roughly $750 million, while the EBITDA midpoint rose only about $22 million. The implied fourth-quarter EBITDA of roughly $227-$237 million is essentially flat to modestly above the third quarter's level.

The call nonetheless preserved a credible growth story on several fronts:

• **Specialty and infusion:** revenue growth accelerated to 34% from 30% in the second quarter, on 29% script growth. BrightSpring has launched 19 LDDs year to date (162 in total), and the 2026 cohort is tracking ahead of last year's.
• **Margins:** Pharmacy segment EBITDA margin edged up to 5.4% from 5.3%, and Provider margin improved to 16.4% from 16.1%.
• **Home and Community Pharmacy:** the most notable inflection was here. Revenue still declined 6% year over year, but that was an improvement from -8% and -9% earlier in the year, and the business is now contributing double-digit EBITDA growth despite an IRA revenue hit management now pegs at about $200 million for 2026, up from about $175 million earlier.

The Provider segment's 31% revenue growth and 58% jump in home health census are heavily acquisition-aided by the Amedisys/LHC branches. Organic home health revenue grew a more modest, though still healthy, 12%.

Forward-looking catalysts lean constructive. Management reiterated 2027 organic Adjusted EBITDA growth of at least 15-20% off a larger 2026 base. BrightSpring was selected for the CMS LEAD ACO program beginning January 2027, though management expects the economics to show up around 2028. With leverage below the 2.5x target and $718 million in cash, management sounded more aggressive on M&A, including somewhat larger deals of up to roughly $20 million of EBITDA.

Bears still have legitimate ammunition:

• The IRA remains a 2027 headwind at roughly half of this year's impact.
• Management acknowledged that part of the third-quarter cash strength was one-time working capital; payables alone swung by $142 million.
• A capital-structure review heading into 2027 could change the leverage profile.
• Corporate costs rose to $53 million from $41 million.
• Hospice CAHPS ratings slipped to 86% from 89%.

The market setup is more complicated than the surprise implies. Investor sentiment remained positive but weakened noticeably, falling from 0.44 to 0.24 between reports. Price action tells a similar story. The stock set its inter-earnings high of $70.05 on the day of the July report, then gave back the entire post-report gain and bottomed at $54.87 in late September. Entering this report at $60.22, it sat 14.0% below that high but 10.6% above its 200-day moving average of $54.46. That means the longer-term trend remains intact even after the pullback. Earnings Whispers' sequential-growth, momentum, and AVWAP trend readings are positive, while the price trend is only neutral, consistent with a stock that has stalled despite improving numbers.

The bottom line is that BrightSpring continues to out-execute its own guidance, with accelerating revenue, expanding segment margins, a rapidly de-levered balance sheet, and an early commitment to double-digit 2027 growth. The debate is shifting from whether the business is working to how durable the drivers are. Pharmacy profit gains rest heavily on specialty mix rather than volume, Provider growth leans on acquisitions, and the implied fourth quarter suggests EBITDA momentum may plateau near current levels. A stock that faded after the last beat-and-raise suggests investors now want evidence of organic, volume-driven durability rather than another guidance increase.